Related Experiment Video
Updated: Jun 24, 2026
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
[Cardiac contractility modulation: a new option for treating systolic heart failure]
D Rottlaender1, G Michels, U C Hoppe
1Klinik III für Innere Medizin, Universitätsklinik zu Köln.
Deutsche Medizinische Wochenschrift (1946)
|March 19, 2009
Summary
Cardiac contractility modulation (CCM) improves exercise capacity and quality of life in advanced systolic heart failure patients. This innovative electrical therapy offers a safe option for enhancing ventricular function.
Area of Science:
- Cardiology
- Biomedical Engineering
- Electrophysiology
Context:
- Advanced systolic heart failure presents significant challenges in improving ventricular contractility.
- Current treatments may be limited by patient characteristics like dyssynchrony or QRS prolongation.
- Cardiac contractility modulation (CCM) offers a novel electrical approach.
Purpose:
- To evaluate the efficacy of CCM treatment in patients with systolic heart failure.
- To assess the impact of CCM on exercise capacity and quality of life.
- To determine the safety profile of CCM implantation and stimulation.
Summary:
- The FIX-CHF-4 trial, a randomized, double-blind, cross-over study, involved 164 patients with ejection fraction ≤35%.
- CCM device implantation is similar to pacemaker procedures, utilizing three electrodes for sensing and stimulation.
- After three months, patients showed improved six-minute walk distance and enhanced quality of life, with unchanged ejection fraction.
Impact:
- CCM demonstrates potential for improving exercise tolerance and quality of life in heart failure patients with left ventricular systolic dysfunction.
- CCM is a safe electrical treatment option for selected heart failure patients.
- Further long-term studies are warranted to assess morbidity and mortality outcomes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...